A pan-tumor study demonstrated GITR expression variability on tumor-infiltrating Tregs and lymphocytes across tumor types and suggested that patients with non-small-cell lung cancer, renal cell carcinoma, and melanoma may mostly benefit from anti-GITR therapies (66). This evidence concerns the gene TNFRSF18 and neoplasm.